Imaging tumors with a special radiodrug targeting HER2 protein

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This project investigates the use of 68Ga-Her2-affibody, a radiodrug targeting the HER2 protein, to assess its diagnostic efficacy and safety in identifying HER2 expression in various cancers. The study aims to provide a novel imaging method that can enhance the determination of HER2 status in breast cancer and offer valuable insights for early diagnosis, accurate staging, and treatment decisions in other malignant tumors like lung, gastrointestinal, and bladder cancers. By utilizing PET imaging, the study seeks to gather comprehensive information that traditional biopsy methods may miss.

Why it matters

Who can join: the full rules

Inclusion Criteria:

\- patients with confirmed or suspected cancer; Signed written informed consent

Exclusion Criteria:

\-

Where it's running

• Peking University First Hospital
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Study coordinator: Lei Yin, Dr
• Email: jack-yin@163.com
• Phone: +8610835725252

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• HR20013 for preventing nausea and vomiting in cancer patients receiving chemotherapy

  This real-world study tests whether HR20013 helps prevent nausea and vomiting in adults with cancer who are getting chemotherapy.

  Recruiting Sun Yat-sen University · Guangzhou, Guangdong · NCT07874308

• Methylscape test in body fluids for multi-cancer detection in Colombia

  A simple blood, urine, or saliva test called Methylscape is being tested to see if it can detect multiple cancers and identify where the signal is coming from, using people with cancer and healthy volunteers in Colombia.

  Recruiting Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo · Bogotá, Bogota D.C. · NCT07741435

• Ready for Safe Cancer Treatment (RESET): A comprehensive perioperative program for surgical patients

  The RESET program tests a structured, multidisciplinary perioperative plan to improve safety and recovery for adults having planned cancer surgery and older adults having planned non cancer-related surgery.

  Recruiting at 2 sites Regional Specialist Hospital in Wroclaw · Wroclaw, Lower Silesian Voivodeship and 1 other locations · NCT07727876

• How environment and biology together predict health, aging, and death

  Researchers are following adults to see how living conditions and biology together relate to aging and life expectancy, by linking personal health data with environmental and social information over time.

  Recruiting Longevity Metrics, Inc. · Boulder, Colorado · NCT07646782

• Metastatic liver cancer patient registry from multiple Chinese centers

  This is a registry that collects real-world data on adults with liver metastases to understand patterns and prognosis and to support future research.

  Recruiting at 2 sites Anhui Provincial Hospital · Bengbu, Anhui and 2 other locations · NCT07602504

• TriAdeno and N-803 vaccine in early prostate cancer on active surveillance

  A vaccine combo called TriAdeno plus the N-803 drug is being tested to see if it can help slow or stop growth in men with early-stage, low- to intermediate-risk prostate cancer who are being watched rather than treated right away.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07574541

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.